Item 2.02 Results of Operations and Financial Condition. On March 5, 2026, Tango Therapeutics, Inc. (“ Tango” or the “ Company”) issued a press release relating to its results of operations and financial condition for the quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The press release, and the information set forth therein (including Exhibit 99.1), is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act”) or otherwise subject to the liabilities of that section. Nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in the filing unless specifically stated so therein.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Tango Therapeutics, Inc. on March 5, 2026 relating to its results of operations and financial condition for the quarter ended December 31, 2025. ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TANGO THERAPEUTICS, INC. Dated: March 5, 2026 By: /s/ Daniella Beckman Name: Daniella Beckman Title: Chief Financial Officer